Smith-Lemli-Opitz (SLO) syndrome is an autosomal recessive disorder characterized by multiple congenital abnormalities and mental retardation. The condition is caused by the deficiency of 7-dehydrocholesterol reductase (DHCR7) which catalyzes the final step in cholesterol biosynthesis. Biochemical diagnosis is based on increased concentration of 7-dehydrocholesterol (7-DHC) in the patient serum. Both life expectancy and quality of life are severely affected by the disease. The estimated prevalence of SLO syndrome ranges between 1:20,000 and 1:40,000 among Caucasians. Although the mutational spectrum of the disease is wide, approximately 10 mutations are responsible for more than 80% of the cases. These mutations show a large interethnic variability. There are no mutation distribution data from Hungary to date. Thirteen patients were diagnosed with SLO syndrome in our laboratory. As first-line tests, serum 7-DHC and total cholesterol were measured and, in positive cases, molecular genetic analysis of the DHCR7 gene was performed. Complete genetic background of the disease could be identified in 12 cases. In 1 case only 1 mutation was detected in a heterozygote form. One patient was homozygous for the common splice site mutation c.964–1G>C, while all other patients were compound heterozygotes. One novel missense mutation, c.374A>G (p.Tyr125Cys) was identified.

Keywords:
Cholesterol, 7-Dehydrocholesterol, DHCR7, Hungary, Mutation, SLO syndrome
1.
Andersson HC, Kratz L, Kelley R: Desmosterolosis presenting with multiple congenital anomalies and profound developmental delay. Am J Med Genet 113:315–319 (2002).
2.
Berry D, Hypponen E: Determinants of vitamin D status: focus on genetic variations. Curr Opin Nephrol Hypertens 20:331–336 (2011).
3.
Brunetti-Pierri N, Corso G, Rossi M, Ferrari P, Balli F, et al: Lathosterolosis, a novel multiple-malformation/mental retardation syndrome due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am J Hum Genet 71:952–958 (2002).
4.
Correa-Cerro LS, Porter FD: 3beta-hydroxysterol delta7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 84:112–126 (2005).
5.
Correa-Cerro LS, Wassif CA, Waye JS, Krakowiak PA, Cozma D, et al: DHCR7 nonsense mutations and characterisation of mRNA nonsense mediated decay in Smith-Lemli-Opitz syndrome. J Med Genet 42:350–357 (2005).
6.
Dörk T, Macek M Jr, Mekus F, Tümmler B, Tzountzouris J, Casals T, et al: Characterization of a novel 21-kb deletion, CFTRdele2,3 (21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum Genet 106:259–268 (2000).
7.
Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik YK, et al: Mutations in the delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci USA 95:8181–8186 (1998).
8.
Honda A, Batta AK, Salen G, Tint GS, Chen TS, Shefer S: Screening for abnormal cholesterol biosynthesis in the Smith-Lemli-Opitz syndrome: rapid determination of plasma 7-dehydrocholesterol by ultraviolet spectrometry. Am J Med Genet 68:288–293 (1997).
9.
Irons M, Elias ER, Salen G, Tint GS, Batta AK: Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet 341:1414 (1993).
10.
Ivady G, Madar L, Nagy B, Gonczi F, Ajzner E, et al: Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis. J Cyst Fibros 10:217–220 (2011).
11.
Kelley RI, Hennekam RC: The Smith-Lemli-Opitz syndrome. J Med Genet 37:321–335 (2000).
12.
Kelley RL, Roessler E, Hennekam RC, Feldman GL, Kosaki K, et al: Holoprosencephaly in RSH/Smith-Lemli-Opitz syndrome: does abnormal cholesterol metabolism affect the function of sonic hedgehog? Am J Med Genet 66:478–484 (1996).
13.
Korade Z, Xu L, Shelton R, Porter NA: Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome. J Lipid Res 51:3259–3269 (2010).
14.
Kozák L, Francová H, Hrabincová E, Procházková D, Jüttnerová V, et al: Smith-Lemli-Opitz syndrome: molecular-genetic analysis of ten families. J Inherit Metab Dis 23:409–412 (2000).
15.
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al: Clustal W and Clustal X version 2.0. Bioinformatics 23:2947–2948 (2007).
16.
Ng PC, Henikoff S: Predicting deleterious amino acid substitutions. Genome Res 11:863–874 (2001).
17.
Ng PC, Henikoff S: Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436–446 (2002).
18.
Porter FD: Malformation syndromes due to inborn errors of cholesterol synthesis. J Clin Invest 110:715–724 (2002).
19.
Porter FD: Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 16:535–541 (2008).
20.
Ren G, Jacob RF, Kaulin Y, Dimuzio P, Xie Y, et al: Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndrome. Mol Genet Metab 104:346–355 (2011).
21.
Shefer S, Salen G, Batta AK, Honda A, Tint GS, et al: Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. J Clin Invest 96:1779–1785 (1995).
22.
Smith DW, Lemli L, Opitz JM: A Newly Recognized Syndrome of Multiple Congenital Anomalies. J Pediatr 64:210–217 (1964).
23.
Szabó GP, Oláh AV, Kozak L, Balogh E, Nagy A, et al: A patient with Smith-Lemli-Opitz syndrome: novel mutation of the DHCR7 gene and effects of therapy with simvastatin and cholesterol supplement. Eur J Pediatr 169:121–123 (2009).
24.
Tint GS, Irons M, Elias ER, Batta AK, Frieden R, et al: Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med 330:107–113 (1994).
25.
Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al: Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180–188 (2010).
26.
Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, et al: Mutations in the human sterol delta7-reductase gene at 11q12–13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet 63:55–62 (1998).
27.
Waterham HR, Wijburg FA, Hennekam RC, Vreken P, Poll-The BT, et al: Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am J Hum Genet 63:329–338 (1998).
28.
Waye JS, Krakowiak PA, Wassif CA, Sterner AL, Eng B, et al: Identification of nine novel DHCR7 missense mutations in patients with Smith-Lemli-Opitz syndrome (SLOS). Hum Mutat 26:59 (2005).
29.
Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, Kraft HG, Moebius FF, et al: Mutational spectrum in the delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet 66:402–412 (2000).
30.
Witsch-Baumgartner M, Löffler J, Utermann G: Mutations in the human DHCR7 gene. Hum Mutat 17:172–182 (2001a).
31.
Witsch-Baumgartner M, Ciara E, Löffler J, Menzel HJ, Seedorf U, et al: Frequency gradients of DHCR7 mutations in patients with Smith-Lemli-Opitz syndrome in Europe: evidence for different origins of common mutations. Eur J Hum Genet 9:45–50 (2001b).
32.
Witsch-Baumgartner M, Gruber M, Kraft HG, Rossi M, Clayton P, et al: Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome. J Med Genet 41:577–584 (2004).
33.
Witsch-Baumgartner M, Clayton P, Clusellas N, Haas D, Kelley RI, et al: Identification of 14 novel mutations in DHCR7 causing the Smith-Lemli-Opitz syndrome and delineation of the DHCR7 mutational spectra in Spain and Italy. Hum Mutat 25:412 (2005).
34.
Witsch-Baumgartner M, Schwentner I, Gruber M, Benlian P, Bertranpetit J, et al: Age and origin of major Smith-Lemli-Opitz syndrome (SLOS) mutations in European populations. J Med Genet 45:200–209 (2008).
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.